GlassScriptPhysician profile
Cheryl Mcneil
NPI 1992019475
$2,175.56
in general payments reported to CMS, 2019-2025
20 companies · $724 in 2025
The $724 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $297 · 2024: $1,155 · 2025: $724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,076 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,075.57 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $397.17 | 2023-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $261.21 | 2024 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.64 | 2023-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $175.80 | 2023-2025 | Verquvo |
| Pfizer INC. | $170.98 | 2023-2025 | |
| Actelion Pharmaceuticals US, INC. | $148.46 | 2024 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $141.17 | 2024-2025 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $123.47 | 2025 | Amvuttra |
| Janssen Pharmaceuticals, INC | $114.36 | 2024 | Xarelto |
| Philips North America LLC | $95.53 | 2023-2025 | (Ck4) Mcot, Mcot, Extended Holter |
| Novartis Pharmaceuticals Corporation | $82.45 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.47 | 2025 | |
| Atricure, INC. | $48.38 | 2024 | |
| Abbott Laboratories | $26.12 | 2025 | Perclose Proglide |
| Novo Nordisk INC | $20.44 | 2025 | Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $19.47 | 2025 | Attruby |
| Azurity Pharmaceuticals, INC. | $18.82 | 2025 | Edarbyclor |
| Astrazeneca Pharmaceuticals LP | $18.78 | 2025 | Wainua |
| Kiniksa Pharmaceuticals, LTD. | $17.30 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $15.54 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Mcneil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.